• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
The reduction in cardiovascular risk in REDUCE-IT is due to eicosapentaenoic acid in icosapent ethyl.REDUCE-IT研究中心血管风险的降低归因于二十碳五烯酸乙酯中的二十碳五烯酸。
Eur Heart J. 2021 Dec 14;42(47):4865-4866. doi: 10.1093/eurheartj/ehab760.
2
Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease.降低残余心血管风险的潜力：2型糖尿病和动脉粥样硬化性心血管疾病VERTIS CV人群中使用二十碳五烯酸乙酯的适用性。
Diabetes Obes Metab. 2023 May;25(5):1398-1402. doi: 10.1111/dom.14965. Epub 2023 Feb 14.
3
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.依泽替米贝降低严重高甘油三酯血症患者心血管风险
N Engl J Med. 2019 Jan 3;380(1):11-22. doi: 10.1056/NEJMoa1812792. Epub 2018 Nov 10.
4
Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction.美国食品药品监督管理局（FDA）对二十碳五烯酸乙酯扩大适应症对进一步降低心血管残留风险的影响。
Future Cardiol. 2021 Jan;17(1):155-174. doi: 10.2217/fca-2020-0106. Epub 2020 Sep 22.
5
Consistency of Benefit of Icosapent Ethyl by Background Statin Type in REDUCE-IT.在REDUCE-IT研究中依洛尤单抗乙酯的获益情况与基础他汀类型的一致性
J Am Coll Cardiol. 2022 Jan 18;79(2):220-222. doi: 10.1016/j.jacc.2021.11.005.
6
Benefits of icosapent ethyl for enhancing residual cardiovascular risk reduction: A review of key findings from REDUCE-IT.依折麦布辛伐他汀乙酯增强残余心血管风险降低的获益：来自 REDUCE-IT 的关键发现综述。
J Clin Lipidol. 2022 Jul-Aug;16(4):389-402. doi: 10.1016/j.jacl.2022.05.067. Epub 2022 Jun 4.
7
Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial.二十碳五烯酸乙酯用于急性冠状动脉综合征：REDUCE-IT试验
Eur Heart J. 2024 Apr 1;45(13):1173-1176. doi: 10.1093/eurheartj/ehad889.
8
Reducing Cardiovascular Disease Risk in Women Beyond Statin Therapy: New Insights 2020.降低女性心血管疾病风险：他汀类药物治疗之外的新见解 2020.
J Womens Health (Larchmt). 2020 Aug;29(8):1091-1100. doi: 10.1089/jwh.2019.8189. Epub 2020 Apr 13.
9
Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis.依泽替米贝在他汀类药物治疗持续高甘油三酯血症的糖尿病女性患者中的血脂作用：ANCHOR 试验亚组分析。
J Womens Health (Larchmt). 2018 Sep;27(9):1170-1176. doi: 10.1089/jwh.2017.6757. Epub 2018 Mar 27.
10
Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies.二十碳五烯酸乙酯（二十碳五烯酸乙酯）：来自 MARINE 和 ANCHOR 研究的残余样颗粒胆固醇的影响。
Atherosclerosis. 2016 Oct;253:81-87. doi: 10.1016/j.atherosclerosis.2016.08.005. Epub 2016 Aug 20.

引用本文的文献

1
EPA Induces an Anti-Inflammatory Transcriptome in T Cells, Implicating a Triglyceride-Independent Pathway in Cardiovascular Risk Reduction.二十碳五烯酸（EPA）在T细胞中诱导抗炎转录组，提示存在一条不依赖甘油三酯的降低心血管风险途径。
JACC Basic Transl Sci. 2025 Mar;10(3):383-395. doi: 10.1016/j.jacbts.2024.09.002. Epub 2024 Oct 30.
2
Classical and Novel Lipid-Lowering Therapies for Diabetic Patients with Established Coronary Artery Disease or High Risk of Coronary Artery Disease-A Narrative Clinical Review.针对已确诊冠心病或有冠心病高风险的糖尿病患者的经典及新型降脂疗法——一项叙述性临床综述
Pharmaceuticals (Basel). 2024 Apr 29;17(5):568. doi: 10.3390/ph17050568.
3
Differential metabolite analysis of the pharmacodynamic differences between different ratios of Dahuang ()-Taoren () herb pair.大黄（）-桃仁（）药对对药效差异的差异代谢物分析。
J Tradit Chin Med. 2024 Jun;44(3):515-523. doi: 10.19852/j.cnki.jtcm.20240423.006.
4
Icosapent ethyl for hypertriglyceridaemia and atherosclerosis: greater RESPECT for increased therapeutic use.二十碳五烯酸乙酯用于治疗高甘油三酯血症和动脉粥样硬化：对其增加治疗用途给予更多关注。
Eur Heart J. 2024 Feb 7;45(6):439-442. doi: 10.1093/eurheartj/ehad668.

本文引用的文献

1
A possible explanation for the contrasting results of REDUCE-IT vs. STRENGTH: cohort study mimicking trial designs.REDUCE-IT 与 STRENGTH 结果对比的可能解释：模拟试验设计的队列研究。
Eur Heart J. 2021 Dec 14;42(47):4807-4817. doi: 10.1093/eurheartj/ehab555.
2
Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies.矿物油：在REDUCE-IT及其他临床研究中的安全性及作为安慰剂的应用
Eur Heart J Suppl. 2020 Oct 6;22(Suppl J):J34-J48. doi: 10.1093/eurheartj/suaa117. eCollection 2020 Oct.
3
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.依泽替米贝降低严重高甘油三酯血症患者心血管风险
N Engl J Med. 2019 Jan 3;380(1):11-22. doi: 10.1056/NEJMoa1812792. Epub 2018 Nov 10.
4
A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins.一项关于二十碳五烯酸对接受他汀类药物治疗的冠心病患者疗效的随机对照试验。
J Cardiol. 2017 Dec;70(6):537-544. doi: 10.1016/j.jjcc.2017.07.007. Epub 2017 Aug 31.
5
Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis.二十碳五烯酸对高胆固醇血症患者主要冠脉事件的影响（日本 EPA 脂质干预研究）：一项随机开放标签、终点设盲的分析。
Lancet. 2007 Mar 31;369(9567):1090-8. doi: 10.1016/S0140-6736(07)60527-3.

The reduction in cardiovascular risk in REDUCE-IT is due to eicosapentaenoic acid in icosapent ethyl.

作者信息

Steg Ph Gabriel, Bhatt Deepak L

机构信息

Université de Paris, FACT (French Alliance for Cardiovascular Trials), Assistance Publique-Hôpitaux de Paris and INSERM U1148, Hôpital Bichat, 46 rue Henri Huchard, Paris 75018, France.

Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.

出版信息

Eur Heart J. 2021 Dec 14;42(47):4865-4866. doi: 10.1093/eurheartj/ehab760.

DOI:10.1093/eurheartj/ehab760
PMID:34734264
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8670779/
Abstract
摘要